SRNE - ソレント・セラピュ―ティクス (Sorrento Therapeutics Inc.) ソレント・セラピュ―ティクス

 SRNEのチャート


 SRNEの企業情報

symbol SRNE
会社名 Sorrento Therapeutics Inc (ソレント・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Sorrento Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in the discovery acquisition development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs resiniferatoxin (RTX) and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs) including biosimilars/biobetters fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform antibody drug conjugates (ADCs) bispecific antibodies (BsAbs) as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.   ソレント・セラピュ―ティクスは米国のバイオ医薬品会社。慢性的な痛みを伴うがん、免疫疾患、感染病などの治療薬の発見・買収・商業化に従事。主要な製品候補には、がんを対象とするミセルジブロック共重合体パクリタキセル製剤「Cynviloq」がある。同社のパイプラインには、臨床前段階のヒト治療抗体も含む。本社はサンディエゴ。   Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
本社所在地 4955 Directors Place San Diego CA 92121 USA
代表者氏名 Henry H. Ji Henry H. Ji
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 858-203-4100
設立年月日 32509
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 162人
url www.sorrentotherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/srne
adr_tso
EBITDA EBITDA(百万ドル) 9.08100
終値(lastsale) 3.99
時価総額(marketcap) 465761781.24
時価総額 時価総額(百万ドル) 402.72630
売上高 売上高(百万ドル) 152.47600
企業価値(EV) 企業価値(EV)(百万ドル) 373.33330
当期純利益 当期純利益(百万ドル) -60.95400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sorrento Therapeutics Inc revenues increased 6% to $10.2M. Net loss increased from $37.3M to $106.4M. Revenues reflect Sales and services increase from $4.5M to $9.9M. Higher net loss reflects Interest Expense increase from $2.8M to $46.1M (expense) Loss (gain) on contingent liabilities an increase from $4.1M (income) to $13.7M (expense) Research and development increase of 25% to $32.6M (expense).

 SRNEのテクニカル分析


 SRNEのニュース

   Sorrento Therapeutics forms Mexico subsidiary in COVID-19 product development push  2021/07/20 19:49:49 Seeking Alpha
   Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento''s Portfolio of COVID-19 Products in Mexico and Parts of Latin America  2021/07/20 19:29:06 Benzinga
Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico. Sorrento''s Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units. Sorrento Therapeutics Mexico will coordinate all activities required for commercialization of COVI-STIX, and for the clinical trials and registration of Sorrento''s portfolio of products for the Mexican and potentially other Latin American Markets. SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE , ", Sorrento", )) today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico ("Sorrento Mexico"), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories. Sorrento Mexico has established offices in Mexico City with Dr.
   Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrentos Portfolio of COVID-19 Products in Mexico and Parts of Latin America  2021/07/20 19:29:00 Intrado Digital Media
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (Sorrento Mexico), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.
   Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management  2021/07/20 16:53:00 Intrado Digital Media
PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced complete enrollment of SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica. SP-102 has received Fast Track status from the FDA.
   Sizing Up Sorrento Therapeutics. AGAIN  2021/07/18 19:35:44 Seeking Alpha
   Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma  2021/04/27 18:30:35 Benzinga
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE ) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI-3031 is based on Sorrento's G-MAB library that has fostered the development of several oncology programs currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently … Full story available on Benzinga.com
   Why Sorrento Therapeutics' Stock Is Trading Higher Today  2021/04/27 17:09:50 Benzinga
Sorrento Therapeutics (NASDAQ: SRNE ) shares are trading higher … Full story available on Benzinga.com
   B.Riley Financial Stick to Their Buy Rating for Sorrento Therapeutics By Investing.com  2021/04/23 06:35:01 Investing.com
B.Riley Financial Stick to Their Buy Rating for Sorrento Therapeutics
   Time to Join Sorrento Therapeutics on its Next Leg Up  2021/04/20 15:15:00 Entrepreneur
We've heard from Sorrento Therapeutics (NASDAQ:SRNE) before, and usually, things are looking good for the biotechnology industry firm. While it's never been a big player—share prices haven't broken the $15 price point in the last five years
   Sorrento's Human Derived Mesenchymal Stem Cells Achieves 100% Discharge Rate In Critically-Ill COVID-19 Patients  2021/04/20 13:51:28 Benzinga
Sorrento Therapeutics Inc (NASDAQ: SRNE ) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS). The study met its primary objective to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells … Full story available on Benzinga.com
   Global Biosimilar Interleukins Market Report 2020-2030: - Major Players are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech and Sunshine Guojian Pharmaceutical  2021/02/05 13:30:00 PR Newswire
DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Biosimilar Interleukins Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Biosimilar Interleukins Global Market Report 2020-30: COVID-19 Growth and Change provides the…
   This post was found on Twitter: whether Sorrento Therapeutics could benefit from a short squeeze – #stocks chatter  2021/02/04 06:05:40 Mehabe
This post was found on Twitter: whether Sorrento Therapeutics could benefit from a short squeeze – #stocks chatter
   Personalized Stem Cells Announces First Patients Treated in COVID-19 Clinical Trial Licensed to Sorrento Therapeutics  2021/02/03 14:00:00 EIN News
Personalized Stem Cells, Inc. announces first patients treated in COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics.
   Sorrento Therapeutics Stock Could More Than Double, Says Analyst | The Motley Fool  2021/01/30 13:27:30 The Motley Fool
The company has several promising treatments in its pipeline.
   Why Sorrento Therapeutics Is Trading Higher Today  2021/01/27 18:59:51 Benzinga
Sorrento Therapeutics (NASDAQ: SRNE ) shares are trading higher … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ソレント・セラピュ―ティクス SRNE Sorrento Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)